GGrantIndex
Sort

82,697 grants matching vaccine development

Novel mechanisms regulating immunity to respiratory virus infection

$913,500
Silke Paust · Jackson Laboratory · R01 · FY2023 · AI

Administrative Core

$913,406
Kevin Sean Kimbro · Morehouse School Of Medicine · U54 · FY2025 · MD

Comparison of High Dose vs. Standard Dose Influenza Vaccines in Lung Allograft Recipients

$913,378
Natasha Bassam Halasa · Vanderbilt University Medical Center · U01 · FY2022 · AI

Development of a Broad-Spectrum Inhibitor against Seasonal and Highly-Pathogenic Influenza Viruses

$913,220
Richard K. Plemper · Georgia State University · R01 · FY2023 · AI

Clinical Evaluation of Novel Adenovirus Prime-Boost HIV-1 Vaccine

$913,169
Raphael Dolin · Beth Israel Deaconess Medical Center · U19 · FY2009 · AI

Rational Design of Immunogens Targeting HIV-1 Quaternary Neutrlizing Epitopes

$913,133
Xiangpeng Kong · New York University School Of Medicine · P01 · FY2017 · AI

Assessing the mechanisms underlying female sex-predominance in Long COVID

$913,012
Michael Joseph Peluso · University Of California, San Francisco · R01 · FY2025 · AI

Structure-Based Design of Drugs and Vaccines for Target*

$912,946
Rutgers The St Univ Of Nj New Brunswick · P01 · FY2004 · GM

Entry and replication of positive-sense, RNA viruses

$912,922
Joseph Marcotrigiano · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI

Novel vaccine strategies to induce V2 apex-directed broad neutralizing antibodies

$912,815
Laurent Karl Verkoczy · San Diego Biomedical Research Institute · R01 · FY2020 · AI

Combining membrane Env vaccine regimens to elicit multiple bnAb lineages and consistent cross-neutralization of HIV

$912,596
Michael B Zwick · Scripps Research Institute, The · R01 · FY2025 · AI

HIV-Receptor Interactions and Related Anti-HIV Strategies

$912,524
Edward Berger · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI

CANDIDA ADHERENCE MYCOLOGY RESEARCH UNIT

$912,518
La Biomed Res Inst/ Harbor Ucla Med Ctr · P01 · FY2002 · AI

Kinetics, evolution, and effector function of Fc repertoires during vaccination with native-like Env trimers

$912,255
D. Noah Sather · Seattle Children'S Hospital · R01 · FY2019 · AI

Pre-clinical Vaccine Development for Respiratory Viruses

$912,113
Wing Pui Kong · National Institute Of Allergy And Infectious Diseases · ZIC · FY2024 · AI

Pre-clinical Vaccine Development for Emerging and Re-emerging Infectious Diseases

$912,113
Wing Pui Kong · National Institute Of Allergy And Infectious Diseases · ZIC · FY2024 · AI

Malaria Vaccine Trials in Mali

$912,060
Christopher V. Plowe · University Of Maryland Baltimore · U19 · FY2009 · AI

Viral priming and targeting NK cells against solid tumor malignancies

$912,000
Jeffrey S Miller · University Of Minnesota · R35 · FY2021 · CA

Viral priming and targeting NK cells against solid tumor malignancies

$912,000
Jeffrey S Miller · University Of Minnesota · R35 · FY2016 · CA

Viral priming and targeting NK cells against solid tumor malignancies

$912,000
Jeffrey S Miller · University Of Minnesota · R35 · FY2017 · CA

Viral priming and targeting NK cells against solid tumor malignancies

$912,000
Jeffrey S Miller · University Of Minnesota · R35 · FY2020 · CA

Viral priming and targeting NK cells against solid tumor malignancies

$912,000
Jeffrey S Miller · University Of Minnesota · R35 · FY2015 · CA

Fusion peptide directed immunogens that elicit neutralizing and protective antibodies in non-human primates

$911,877
Andrew Barrett Ward · Scripps Research Institute, The · R01 · FY2020 · AI

An Orally Delivered Booster Vaccine Candidate for Hepatitis B

$911,830
John A. Howard · Applied Biotechnology Institute · R44 · FY2013 · AI

Vector Biological Studies in Leishmaniasis

$911,807
David Sacks · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI